LY-334370

LY-334370
Clinical data
Other names	LY334370; LY-334,370
Drug class	Serotonin 5-HT1F receptor agonist
ATC code	None;
Identifiers
	IUPAC name 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide;
CAS Number	182563-08-2;
PubChem CID	5311258;
IUPHAR/BPS	20; 151;
ChemSpider	4470773;
UNII	5Q7I1WL2UY;
ChEMBL	ChEMBL101690;
CompTox Dashboard (EPA)	DTXSID40415518 ;
Chemical and physical data
Formula	C21H22FN3O
Molar mass	351.425 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)NC(=O)C4=CC=C(C=C4)F;
	InChI InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26); Key:MDMJLMDBRQXOOI-UHFFFAOYSA-N;

LY-334370 is a selective serotonin 5-HT_1F receptor agonist of the triptan and piperidinylindole families which was under development by Eli Lilly and Company for the treatment of migraine headaches. The drug showed efficacy in a phase II clinical trial but further development was halted due to toxicity detected in animals. It is closely related to tryptamines like the psychedelic drug dimethyltryptamine (DMT), but is not technically a tryptamine itself and is instead a piperidinylindole similarly to naratriptan.